SHR-A2009 / Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SHR-A2009 / Jiangsu Hengrui Pharma
NCT06671379: A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

Recruiting
3
500
RoW
SHR-A2009 monotherapy, platinum-based dual-agent chemotherapy
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
12/26
06/27
CAP 02, NCT03736863: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Recruiting
2
147
RoW
Apatinib+ SHR-1210（Camrelizumab）, Apatinib+ SHR-1316（Adebrelimab）, SHR-1316（Adebrelimab）+SHR-A2009
The First Affiliated Hospital of Zhengzhou University
Esophageal Cancer
06/21
12/25
NCT06465238: Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

Not yet recruiting
2
30
RoW
SHR-A2009, SHR-A1921
Henan Cancer Hospital
NSCLC
06/26
06/27
NCT06649331: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Recruiting
2
120
RoW
SHR-A1811, SHR-A1921, SHR-A2009, SHR-A2102
Fudan University
Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer
09/26
09/27
BCTOP-L-M05, NCT05594095: SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
2
620
RoW
PIK3CA inhibitor, AKT inhibitor, Carrelizumab, SHR1210, Famitinib, Fluzoparib, SHR3162, Dalpiciclib, SHR6390, SHR-A1811, Everolimus, Aromatase Inhibitors or Fulvestrant, Goserelin, TPC, Sorafenib, Apatinib, SHR-A1921, SHR-A2102, SHR-A2009, SHR-1167, SHR-6209, bevacizumab
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University, Nanchang People's Hospital, Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Nantong University, The First Hospital of Jilin University
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
12/25
12/26
SHR-A2009-201, CTR20233099: An open-label, multicenter phase IB/II clinical study of the safety, tolerability and efficacy of SHR-A2009 for injection in combination with anti-tumor therapy in patients with advanced solid tumors

Recruiting
1b/2
270
China
SHR-A2009 - Jiangsu Hengrui Pharma, adebrelimab (SHR-1316) - Jiangsu Hengrui Pharma, Ameile (aumolertinib) - Jiangsu Hansoh Pharma
Shengdia Biopharmaceutical Co., Ltd
Advanced solid tumors
 
 
NCT06222879: Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Recruiting
1/2
350
RoW
HRS-8080; SHR-A1811, HRS-8080; SHR-A2009, SHR-A2009; SHR-1316
Shandong Suncadia Medicine Co., Ltd.
Breast Cancer
10/26
10/26
NCT06474455: A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
156
RoW
SHR-9839 ；SHR-A2009, SHR-9839 ； SHR-A1921, SHR-9839 ； pemetrexed ；carboplatin, SHR-9839 ； Almonertinib
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
06/26
06/27
SHR-A2009-201, NCT06092268: A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
270
NA
SHR-A2009 for injection ； Almonertinib Mesilate Tablets, SHR-A2009 for injection；Adebrelimab Injection
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
12/25
12/25
SHR-A2009-I-101, NCT05114759: A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Recruiting
1
132
Japan, RoW
SHR-A2009
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
12/23
12/24
SHR-A2009-I-102, NCT05394818: The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Completed
1
19
RoW
SHR-A2009
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor
04/24
04/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SHR-A2009 / Jiangsu Hengrui Pharma
NCT06671379: A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

Recruiting
3
500
RoW
SHR-A2009 monotherapy, platinum-based dual-agent chemotherapy
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
12/26
06/27
CAP 02, NCT03736863: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Recruiting
2
147
RoW
Apatinib+ SHR-1210（Camrelizumab）, Apatinib+ SHR-1316（Adebrelimab）, SHR-1316（Adebrelimab）+SHR-A2009
The First Affiliated Hospital of Zhengzhou University
Esophageal Cancer
06/21
12/25
NCT06465238: Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

Not yet recruiting
2
30
RoW
SHR-A2009, SHR-A1921
Henan Cancer Hospital
NSCLC
06/26
06/27
NCT06649331: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Recruiting
2
120
RoW
SHR-A1811, SHR-A1921, SHR-A2009, SHR-A2102
Fudan University
Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer
09/26
09/27
BCTOP-L-M05, NCT05594095: SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
2
620
RoW
PIK3CA inhibitor, AKT inhibitor, Carrelizumab, SHR1210, Famitinib, Fluzoparib, SHR3162, Dalpiciclib, SHR6390, SHR-A1811, Everolimus, Aromatase Inhibitors or Fulvestrant, Goserelin, TPC, Sorafenib, Apatinib, SHR-A1921, SHR-A2102, SHR-A2009, SHR-1167, SHR-6209, bevacizumab
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University, Nanchang People's Hospital, Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Nantong University, The First Hospital of Jilin University
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
12/25
12/26
SHR-A2009-201, CTR20233099: An open-label, multicenter phase IB/II clinical study of the safety, tolerability and efficacy of SHR-A2009 for injection in combination with anti-tumor therapy in patients with advanced solid tumors

Recruiting
1b/2
270
China
SHR-A2009 - Jiangsu Hengrui Pharma, adebrelimab (SHR-1316) - Jiangsu Hengrui Pharma, Ameile (aumolertinib) - Jiangsu Hansoh Pharma
Shengdia Biopharmaceutical Co., Ltd
Advanced solid tumors
 
 
NCT06222879: Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Recruiting
1/2
350
RoW
HRS-8080; SHR-A1811, HRS-8080; SHR-A2009, SHR-A2009; SHR-1316
Shandong Suncadia Medicine Co., Ltd.
Breast Cancer
10/26
10/26
NCT06474455: A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
156
RoW
SHR-9839 ；SHR-A2009, SHR-9839 ； SHR-A1921, SHR-9839 ； pemetrexed ；carboplatin, SHR-9839 ； Almonertinib
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
06/26
06/27
SHR-A2009-201, NCT06092268: A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
270
NA
SHR-A2009 for injection ； Almonertinib Mesilate Tablets, SHR-A2009 for injection；Adebrelimab Injection
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
12/25
12/25
SHR-A2009-I-101, NCT05114759: A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Recruiting
1
132
Japan, RoW
SHR-A2009
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
12/23
12/24
SHR-A2009-I-102, NCT05394818: The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Completed
1
19
RoW
SHR-A2009
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor
04/24
04/24

Download Options